Asset profile
insulin glargine · Lantus / Toujeo
Peptide
Evidence outlook
Approved: Type 2 Diabetes
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
80 competitors in this universe: 19 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Insulin Glargine (Lantus / Toujeo): this drug | Approved | Peptide | Insulin receptor (basal) | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Detemir (Levemir) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Icodec (Awiqli) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor (basal) | ||
| LY2963016 (Basaglar) | Approved | Peptide | Insulin receptor (basal) | ||
| LY900014 (Lyumjev) | Approved | Peptide | Insulin receptor (basal) | ||
| SAR341402 | Approved | Peptide | Insulin receptor (basal) | ||
| GZR33 | Phase 3 | Peptide | Insulin receptor (basal) | ||
| IcoSema (Kyinsu) | Phase 3 | Peptide | Insulin receptor (basal), GLP-1 receptor | ||
| INS068 | Phase 3 | Peptide | Insulin receptor (basal) | ||
| Insulin Efsitora Alfa | Phase 3 | Protein / enzyme therapeutic | Insulin receptor (basal) | ||
| ORMD-0801 | Phase 3 | Peptide | Insulin receptor (basal) | ||
| THDB0206 | Phase 3 | Peptide | Insulin receptor (basal) |
…and 65 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
11 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
April 2027 (1)
What to watch
June 2027 (2)
December 2027 (1)
What to watch
2028 (3)
February 2028 (1)
What to watch
May 2028 (1)
What to watch
June 2028 (1)
What to watch
2029 (1)
December 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.